Fatih Oguz Onder

Fatih Oguz Onder

Auto-generated profile, based on publicly available information

Fatih Oguz Onder

Department of Gastroenterology, Türkiye Yüksek İhtisas Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2008 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
CYCihan Yurdaydin
Cihan Yurdaydin
HBH. Bozkaya
H. Bozkaya
FÖF. O. Önder
F. O. Önder
HŞH. Şentürk
H. Şentürk
HKH. Karaaslan
H. Karaaslan
AÖA. Özden
A. Özden

7 February 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CYCihan Yurdaydin
Cihan Yurdaydin
OKOnur Keskin
Onur Keskin
ÇKÇağdaş Kalkan
Çağdaş Kalkan
FKFatih Karakaya
Fatih Karakaya
AÇAysun Çalişkan
Aysun Çalişkan
RIRamazan Idilman
Ramazan Idilman
Interferon is the only treatment option in chronic delta hepatitis (CDH). A CDH database (333 patients, 161 with interferon treatment history) was analyzed for effects of treatment duration on virologic response and clinical outcomes. Ninety-nine CDH patients who received at least 6 months of interferon were selected. Maintained virologic response (MVR) was defined as hepatitis D virus RNA negative for 2 years after treatment discontinuation. Cumulative median interferon treatment duration was 24 months (range 6–126 months), with a median of 2 courses (range 1–8). Post-treatment median follow-up was 55 months (24–225 months). Thirty-five patients achieved MVR. Cumulative probability of MVR increased with treatment duration and reached 50% at 5 years. Patients with MVR were less likely to die from liver disease or develop complications compared to patients without MVR (P = .032, P = .006, respectively). Cirrhosis at baseline and no response to therapy (odds ratio 16.1 and 5.23, respectively) predicted an adverse endpoint. Hepatitis B surface antigen clearance occurred in 37% of patients with MVR. Viral response to interferon increases with treatment duration and favorably affects the natural course of disease. Interferon treatment duration has to be individualized with careful post-treatment assessment.

12 December 2011 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MTMehlika Toy
Mehlika Toy
FÖFatih Oguz Önder
Fatih Oguz Önder
TWTanja Wörmann
Tanja Wörmann
ABA Mithat Bozdayi
A Mithat Bozdayi
SSSolko W Schalm
Solko W Schalm
CYCihan Yurdaydin
Cihan Yurdaydin
To provide a clear picture of the current hepatitis B situation, the authors performed a systematic review to estimate the age- and region-specific prevalence of chronic hepatitis B (CHB) in Turkey.

6 August 2007 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
CYCihan Yurdaydin
Cihan Yurdaydin
HBH. Bozkaya
H. Bozkaya
HKH. Karaaslan
H. Karaaslan
FÖF. O. Önder
F. O. Önder
ÖEÖ. E. Erkan
Ö. E. Erkan
ÖUÖ. Uzunalimoğlu
Ö. Uzunalimoğlu

20 June 2012 in Liver International
Verified
Journal Article
Closed access
PDF file
BHBenjamin Heidrich
Benjamin Heidrich
BSBeatriz C. Serrano
Beatriz C. Serrano
RIRamazan Idilman
Ramazan Idilman
GKGökhan Kabaçam
Gökhan Kabaçam
BBBirgit Bremer
Birgit Bremer
HWHeiner Wedemeyer
Heiner Wedemeyer

9 May 2012 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
GKGökhan Kabaçam
Gökhan Kabaçam
FÖF. Oğuz Önder
F. Oğuz Önder
MYMustafa Yakut
Mustafa Yakut
GSGülseren Seven
Gülseren Seven
SKSenem C. Karatayli
Senem C. Karatayli
CYCihan Yurdaydin
Cihan Yurdaydin
Background. Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infection and cause disease. Entecavir is a nucleoside analog with potent antiviral efficacy, and in the woodchuck animal model it also decreased hepatitis B virus (HBV) cccDNA and woodchuck surface antigen. The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD). Methods. This single-center study was conducted in patients with compensated liver disease. All patients had to have detectable hepatitis HDV RNA and elevated levels of alanine aminotransferase (ALT). Entecavir was given at a dosage of 1 mg/d for 1 year. The primary end point was achievement of undetectable HDV RNA at the end of treatment. Results. Thirteen consecutive patients were assessed. All patients had detectable HDV RNA, and 8 had detectable HBV DNA at baseline. At the end of treatment, HBV DNA became undetectable in all patients (P = .001). No significant decline in HDV RNA, ALT, or quantitative HBsAg levels was observed. The primary end point of undetectable HDV RNA at the end of treatment was achieved in 3 patients who had significantly lower baseline HDV RNA levels than nonresponders (2.99 log10 copies/mL ± .70 vs 4.68 ± .97; P = .0185). In all 3 patients, ALT levels were also normal at the end of treatment. Conclusions. One year of entecavir treatment is ineffective in CHD. Any generalized beneficial effect of nucleoside/nucleotide analog treatment may necessitate prolonged treatment. Patients with CHD with HBV dominance, which is likely to occur in the later phases of CHD, may be a reasonable patient cohort in which to target nucleoside/nucleotide analog therapy.